Trial Performance
| Disease indication | Protocol |
Phase
|
Number of pts
|
Number of sites
|
Services provided |
| Breast, metastatic | CECOG-BM1 |
III
|
259
|
30
|
protocol development, site contracting, statistical analysis, medical writing |
| Breast | CECOG/BC2.2.005 |
II
|
50
|
3
|
Protocol development, site contracting, med. Writing, statistical analysis |
| Breast | CECOG/BC1.3.002 |
III
|
100
|
14
|
Protocol development, site contracting |
| Breast, recurrent or metastatic | CECOG/BC1.3.005 |
III
|
560
ongoing |
56
|
Protocol development, site contracting, statistical analysis, med. writing |
| Lung, NSCLC | CECOG/NSCLC2.2.001 |
II
|
80
|
6
|
Protocol development, site contracting, statistical analysis |
| Lung, NSCLC | NSCLC 1 |
II
|
352
|
24
|
Protocol development, site contracting |
| Colorectal | CORE 1.2.001 |
II
|
150
|
25
|
Protocol development, site contracting, statistical analysis |
| Colorectal | CORE 1.2.002 |
II
|
150
|
22
|
Protocol development, site contracting, statistical analysis, med. writing |
| Colorectal, metastatic | DREAM |
III
|
50
|
5
|
Protocol development, site contracting |
| GIST | GIST1.2.001 |
III
|
125
|
18
|
Protocol development, site contracting |
CECOG participated in the following trials: |
|||||
| Lung, NSCLC | H3E-MC-JMEN |
III
|
168
|
14
|
Protocol development, site contracting |
| Pancreas |
III
|
319
|
CECOG / SAKK Cooperative Trial
|
Protocol development, patient recruitment, site contracting, med. writing | |